Tirzepatide（mounjaro）5mg 10mg 15mg injection
Tirzepatide
He noiʻi ʻo Tirzepatide i hoʻokahi pule i kēlā me kēia pule, ʻelua glucose-dependent insulinotropic polypeptide a me glucagon-like peptide-1 receptor agonist e hoʻohui i nā hana o nā incretins ʻelua i hoʻokahi mole.
Hoʻohana ʻo Tirzepatide i nā Hormone kūlohelohe e hoʻoulu ai i ka manaʻo piha
Ke hana nei ʻo Tirzepatide ma ka hoʻohālike ʻana i nā hormones GLP-1 a me GIP i hūnā maoli ʻia e ka ʻōpū ma hope o ka ʻai ʻana, e koi ana i ka huna ʻana o ka insulin.Hoʻemi pū ia i ka ʻai ma o ka hoʻolohi ʻana i ka manawa e hoʻokahe ai ka ʻōpū a me ka launa pū ʻana me nā wahi o ka lolo e hoʻopaʻa ana i nā mea loaʻa GLP-1 e hōʻailona ai i ka māʻona.
ʻO Tirzepatide kahi lāʻau lapaʻau hou i ʻae ʻia e FDA no ka mālama ʻana i ka maʻi diabetes type 2.Hāʻawi ʻia i kāna mau waiwai hoʻemi kaumaha,tirzepatidee hoʻohana i waho-label no ka mālama ʻana i ka momona.Hana ia ma ke ʻano he ʻelua GLP-1 agonist a me GIP agonist e hoʻonui i nā pono like i ʻike ʻia me nā lāʻau GLP-1 e like me semaglutide.Hoʻohana ʻia ia i kēia manawa ma ke ʻano he lāʻau lapaʻau maʻi diabetes laina lua, e like me nā lāʻau lapaʻau GLP-1, a hāʻawi ʻia ma ke ʻano he injectable subcutaneous i hoʻokahi pule i hoʻokahi pule.
ʻO Tirzepatide kahi mea hoʻokipa glucose-dependent insulinotropic polypeptide (GIP) a me glucagon-like peptide-1 (GLP-1) recepto agonist, ʻo ia ka FDA-apono ʻia no ka mālama ʻana i ka maʻi maʻi type 2.He mea nui e hoʻomaopopo ʻaʻole ʻae ʻia ka tirzepatide no ka mālama ʻana i ka maʻi diabetes type-1 a ʻaʻole i aʻo ʻia i nā mea maʻi me ka pancreatitis.ʻO Tirzepatide kahi mea hoʻokipa GIP a me GLP-1 receptor agonist, e alakaʻi ana i ka hoʻomaikaʻi maikaʻi ʻana i ka mana glycemic i nā maʻi maʻi type 2 a me ka hōʻemi nui o ke kaumaha.
Ua ʻae ka FDA iā Tirzepatide i Mei 2022. Hiki ke hoʻohana ʻia ʻo Tirzepatide ma waho-label no ka mālama ʻana i ka momona.Hoʻohana ʻia i kēia manawa ma ke ʻano he lāʻau lapaʻau maʻi diabetes lua, e like me nā lāʻau GLP-1 e like me semaglutide.He lāʻau injectable subcutaneous i hoʻokahi pule me ka piʻi ʻana o ka nui.
Ua hōʻike ʻia ka ʻikepili lapaʻau o kēia manawa ʻoi aku ka maikaʻi o ka tirzepatide ma mua o ka placebo i ka hoʻomaikaʻi ʻana i nā pae hemoglobin A1C.Ua hōʻike ka SURPASS-5 hoʻokolohua hoʻokolohua he -2.11% ka emi ʻana o nā pae hemoglobin A1C ma 5mg i kēlā me kēia pule dosing, hoʻohālikelike ʻia me -0.86% me kahi placebo.Ma ka helu kiʻekiʻe loa o 15 mg i kēlā me kēia pule, ua alakaʻi ʻo tirzepatide i kahi -2.34% hōʻemi i ka hemoglobin A1C.Ua hōʻike ʻia kēia ma luna o 40 mau pule.Ua ʻike ʻia kahi hōʻemi kaumaha o 5.4 kg me 5mg o ka tirzepatide dosing, a ua ʻike ʻia kahi hōʻemi 10.5 kg me 15 mg dosing.ʻO kēia hoʻopili pili ʻana me ka pohō kaumaha e like me ka semaglutide, kahi lāʻau GLP-1 maʻamau i hoʻohana ʻia no ka mālama ʻana i ke kaumaha.
Hoʻohālikelike, ua hōʻike ʻia ka tirzepatide e hana like me nā lāʻau GLP-1 akā me ka ʻoi aku ka maikaʻi.Hāʻawi ʻia i kāna mau waiwai hoʻemi kaumaha a me ka nele o ka ʻawaʻawa o ka ate, hiki ke pāʻani i kahi kuleana ʻole i ka mālama ʻana i ka maʻi ʻaʻai momona ʻole (NAFLD) pū kekahi.
HOOLAHA
Hoʻouna mākou ma ka honua holoʻokoʻa.
Pono ʻoe e nīnau i kāu mau kūkākūkā olakino ma mua o ka hoʻohana ʻana i ka huahana.
